• Ultragreen.ai expects new US competitors to weigh on fourth-quarter FY2026 performance, with the full-year impact extending into FY2027.
• ICG products from Zydus and Provepharm are entering the market, leaving US pricing, product mix and demand uncertain.
• Plans include relaunching generic ICG alongside branded IC-GREEN as a competitively priced alternative and accelerating the NIR camera rollout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragreen.ai Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 6FJNMAM0WORSPYS2) on October 28, 2026, and is solely responsible for the information contained therein.